SCHEMBL7898013

SCHEMBL7898013

CC1CN(c2ccc(OCc3ccccc3)cc2)CCC1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.48
ACACB O00763 1/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 3/20 0.45
MMP13 P45452 1/20 0.45
MAPT P10636 2/20 0.44
MCHR1 Q99705 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
HRH3 Q9Y5N1 3/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
S1PR5 Q9H228 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7898016 1.00 GRM2 (0.48) GRM2ACACBNPC1RAB9AL3MBTL1
SCHEMBL27535346 0.89 TP53 (0.43) GRM2ACACBNPC1RAB9AL3MBTL1
SCHEMBL7898037 0.82 ACACB (0.45) ACACBNPC1RAB9AKDM4EMAPT
SCHEMBL7898038 0.82 ACACB (0.45) ACACBNPC1RAB9AKDM4EMAPT
SCHEMBL7898035 0.82 ACACB (0.45) ACACBNPC1RAB9AKDM4EMAPT
SCHEMBL735870 0.80 MAPT (0.52) NPC1RAB9AL3MBTL1PKMSMN1; SMN2
SCHEMBL27473865 0.77 HRH3 (0.54) ACACBNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL13279833 0.76 GSTP1 (0.52) NPC1RAB9AL3MBTL1PKMSMN1; SMN2
SCHEMBL22411529 0.76 RAB9A (0.53) ACACBNPC1RAB9AKDM4EMAPT
SCHEMBL10437652 0.76 HRH3 (0.58) NPC1RAB9AL3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed